Vir Biotechnology, Inc. and GlaxoSmithKline plc (GSK) announced an agreement to expand their existing collaboration to include the research and development of new therapies for influenza and other respiratory viruses.
Expanded Collaboration to Advance New Therapeutics for Respiratory Viruses
Vir Biotechnology, Inc. and GlaxoSmithKline plc (GSK) announced an agreement to expand their existing collaboration to include the research and development of new therapies for influenza and other respiratory viruses.
Editorial: U.S. FDA’s Experience with COVID-19 Antibody Tests
An editorial published by The New England Journal of Medicine (NEJM) highlights ‘establishing robust and coordinated national and international mechanisms for generating evidence and gathering, sharing, and disseminating information will be critical to ending the current pandemic and addressing future public health emergencies.’
ED Visit Volume Dropped for Mental Health, Substance Use Early in Pandemic
However, from March 15 to Oct. 10, 2020, higher median emergency department visit rates seen when compared with 2019
Zinc, Ascorbic Acid Do Not Cut Symptom Duration in SARS-CoV-2
No difference in length of time required to achieve 50 percent reduction in symptoms seen with supplements versus usual care
CRISPR-Based Testing Feasible for SARS-CoV-2 Screening
Study finds technology shows concordance with PCR testing and can detect leading edge of outbreak in asymptomatic people
Canadian Study Confirms COVID-19 More Serious Than Influenza
Relative risks increased for in-hospital mortality, ICU use, hospital length-of-stay during first wave of pandemic
Prevalence of SARS-CoV-2 Infection Low in Young Children
Few children or day care center staff had SARS-CoV-2 infection during lockdown; seropositive children more likely exposed at home
U.S. Calls for Swift Action on New Ebola Outbreaks
Ebola has an average case fatality rate of 50 percent, though it can vary by outbreak